Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study
Diabetes, Obesity and Metabolism · 2026-02 · 28 (2) · 1057-1067
DOI: 10.1111/dom.70279 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 12.11.2025. Verfasst von Maria J Alfonso Arvez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicine Use and Safety, Faculty of Pharmacy and Peharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hospitalization, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Aims
To assess the association between initiating sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared to dipeptidyl peptidase‐4 (DPP4) inhibitors and the rate of infection‐related hospitalisations among individuals with type 2 diabetes following hospital discharge. Materials and Methods In this active comparator, new user cohort study, we compared rates of infection‐related hospitalisations among new users of SGLT2 inhibitors to new users of DPP4 inhibitors over 2 years post‐discharge. We analysed data from all public and private hospitals in Victoria, Australia. Weighted incidence rate ratios (wIRRs) and 95% CIs were estimated using negative binomial regression with inverse probability of treatment weighting.
Results
New users of SGLT2 inhibitors had a lower rate of overall infection‐related hospitalisations (wIRR 0.74, 95% CI 0.71–0.77), and specifically for sepsis (wIRR 0.60, 95% CI 0.54–0.66), pneumonia (wIRR 0.61, 95% CI 0.55–0.66), gastrointestinal infections (wIRR 0.77, 95% CI 0.70–0.85), urinary tract infections (wIRR 0.38, 95% CI 0.34–0.43), respiratory tract infections (wIRR 0.68, 95% CI 0.63–0.74), influenza (wIRR 0.63, 95% CI 0.48–0.83) and kidney infections (wIRR 0.49, 95% CI 0.34–0.71). No significant differences were observed for rates of hospitalisation for cellulitis (wIRR 1.04, 95% CI 0.98–1.10). In contrast, hospitalisations for osteomyelitis (wIRR 1.14, 95% CI 1.02–1.27), foot infections (wIRR 1.25, 95% CI 1.19–1.31), and genital mycotic infections (wIRR 1.48, 95% CI 1.24–1.76) were higher in new users of SGLT2 inhibitors.
Conclusions
Initiating SGLT2 inhibitors is associated with lower overall rates of infection‐related hospitalisations over 2 years. However, the association between SGLT2 inhibitors and infection‐related hospitalisations is dependent on the type of infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Peharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
ORCID-Profile: Maria J Alfonso Arvez, George S Q Tan, Zanfina Ademi, Jenni Ilomäki, J Simon Bell
Zitieren
APA
Alfonso Arvez, M. J., Tan, G. S. Q., Ademi, Z., Ilomäki, J., & Bell, J. S. (2026). Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study. Diabetes, Obesity and Metabolism, 28(2), 1057-1067. https://doi.org/10.1111/dom.70279
Vancouver
Alfonso Arvez MJ, Tan GSQ, Ademi Z, Ilomäki J, Bell JS. Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study. Diabetes, Obesity and Metabolism. 2026;28(2):1057-1067. doi:10.1111/dom.70279
BibTeX
@article{AlfonsoArvez2026,
author = {Alfonso Arvez, Maria J and Tan, George S Q and Ademi, Zanfina and Ilomäki, Jenni and Bell, J Simon},
title = {Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {2},
pages = {1057--1067},
doi = {10.1111/dom.70279}
}
EUVIMED